Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

被引：20

作者：

Bendell, Johanna C. ^{[1
]}

Bedard, Philippe ^{[2
]}

Bang, Yung-Jue ^{[3
]}

LoRusso, Patricia ^{[4
]}

Hodi, Stephen ^{[5
]}

Gordon, Michael ^{[6
]}

D'Angelo, Sandra ^{[7
]}

Desai, Jayesh ^{[8
]}

Garralda, Elena ^{[9
]}

Italiano, Antoine ^{[10
]}

Myung-Ju Ahn ^{[11
]}

Cervantes, Andres ^{[12
]}

Wainberg, Zev ^{[13
]}

Calvo, Emiliano ^{[14
]}

Gil-Martin, Marta ^{[15
]}

Martinez-Garcia, Maria ^{[16
]}

Bahleda, Rastilav ^{[17
]}

Cassier, Philippe ^{[18
]}

Delord, Jean-Pierre ^{[19
]}

Prawira, Amy ^{[20
]}

Melero, Ignacio ^{[21
]}

Emens, Leisha ^{[22
]}

Romano, Emanuela ^{[23
]}

Miller, Karen ^{[24
]}

Hsieh, Robert W. ^{[25
]}

Xue, Cloris ^{[24
]}

Morrissey, Kari ^{[24
]}

Twomey, Patrick ^{[24
]}

Gash, Kelly ^{[24
]}

Patil, Namrata S. ^{[24
]}

Grogan, Jane ^{[24
]}

Meng, Raymond ^{[24
]}

Cho, Byoung ^{[26
]}

Kim, Tae Won ^{[27
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Princess Margaret Hosp, Toronto, ON, Canada

[3] Seoul Natl Univ Hosp, Seoul, South Korea

[4] Yale Canc Ctr, New Haven, CT USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] HonorHlth Res Inst, Scottsdale, AZ USA

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Inst Bergonie CLCC, Bordeaux, France

[11] Samsung Med Ctr, Seoul, South Korea

[12] Hosp Clin Univ Valencia, Valencia, Spain

[13] Univ Calif Los Angeles, Los Angeles, CA USA

[14] Hosp Univ HM Sanchinarro CIOCC, Madrid, Spain

[15] ICO Hosp, Barcelona, Spain

[16] Hosp del Mar, Barcelona, Spain

[17] Inst Gustave Roussy, Villejuif, France

[18] Ctr Leon Berard Ctr Reg Lutte Canc Rhone Alpes, Lyon, France

[19] Inst Claudius Regaud, Toulouse, France

[20] St Vincents Hosp, Darlinghurst, NSW, Australia

[21] Clin Univ Navarra, Navarra, Spain

[22] Johns Hopkins Univ, Baltimore, MD USA

[23] Inst Curie, Paris, France

[24] Genentech Inc, San Francisco, CA 94080 USA

[25] F Hoffmann La Roche, Mississauga, ON, Canada

[26] Sarah Cannon Res Inst, Seoul, South Korea

[27] Asan Med Ctr, Seoul, South Korea

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-CT302

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT302

引用

页数：3

共 50 条

[1] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
Yamamoto, Noboru
Koyama, Takafumi
Sato, Jun
Yoshida, Tatsuya
Sudo, Kazuki
Iwasa, Satoru
Kondo, Shunsuke
Yonemori, Kan
Kawasaki, Atsuko
Satake, Kyoko
Shibata, Shoyo
Shimizu, Toshio
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 109 - 115
[2] Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
Wainberg, Z.
Matos, I.
Delord, J.
Cassier, P.
Gil-Martin, M.
Kim, T.
LoRusso, P.
Bahleda, R.
Italiano, A.
Mendus, D.
Hoang, T.
Xue, C.
Wen, X.
Carvalho, O.
Pham, T.
Patil, N.
Meng, R.
Bendell, J.
Cervantes, A.
Cho, B.
ANNALS OF ONCOLOGY, 2021, 32 : S227 - S228
[3] AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
Frentzas, Sophia
Kao, Steven
Gao, Rang
Zheng, Hao
Rizwan, Ahsan
Budha, Nageshwar
Pedroza, Luz de la Hoz
Tan, Wei
Meniawy, Tarek
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
[4] Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors A Phase 1a/1b Nonrandomized Controlled Trial
Kim, Tae Won
Bedard, Philippe L.
Lorusso, Patricia
Gordon, Michael S.
Bendell, Johanna
Oh, Do-Youn
Ahn, Myung-Ju
Garralda, Elena
D'Angelo, Sandra P.
Desai, Jayesh
Hodi, F. Stephen
Wainberg, Zev
Delord, Jean-Pierre
Cassier, Phillippe A.
Cervantes, Andres
Gil-Martin, Marta
Wu, Benjamin
Patil, Namrata S.
Jin, Yanling
Hoang, Tien
Mendus, Diana
Wen, Xiaohui
Meng, Raymond
Cho, Byoung Chul
JAMA ONCOLOGY, 2023, 9 (11) : 1574 - 1582
[5] AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
Frentzas, Sophia
Meniawy, Tarek
Kao, Steven Chuan-Hao
Wang, Ruihua
Zuo, Yunxia
Zheng, Hao
Tan, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors (jan, 10.1007/s00280-023-04627-3, 2024)
Yamamoto, Noboru
Koyama, Takafumi
Sato, Jun
Yoshida, Tatsuya
Sudo, Kazuki
Iwasa, Satoru
Kondo, Shunsuke
Yonemori, Kan
Kawasaki, Atsuko
Satake, Kyoko
Shibata, Shoyo
Shimizu, Toshio
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 491 - 491
[7] A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.
Janku, Filip
Strauss, James
Karim, Raghad
Olszanski, Anthony J.
Luke, Jason J.
Leach, Kevin
Iyer, Radhakrishnan
Abbas, Atif
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors
Mendelson, David S.
Rosen, Lee S.
Robert, Francisco
Chiorean, E. Gabriela
Goldman, Jonathan Wade
Seon, Ben K.
Alvarez, Delia
Adams, Bonne J.
Theuer, Charles P.
Leigh, Bryan R.
Gordon, Michael S.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[9] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
Wu, Yi-Long
Cheng, Ying
Chen, Huajun
Tu, Haiyan
Xu, Chongrui
Wang, Zhen
Liu, Ying
Xin, Ying
Lou, Haizhou
Wang, Wei
Chin, Kevin
Li, Dandan
Zhao, Di
Gao, Yanfei
Xu, Wenping
Pan, Hongming
FUTURE ONCOLOGY, 2022,
[10] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
Wu, Yi-Long
Cheng, Ying
Chen, Huajun
Tu, Haiyan
Xu, Chongrui
Wang, Zhen
Liu, Ying
Xin, Ying
Lou, Haizhou
Wang, Wei
Chin, Kevin
Li, Dandan
Zhao, Di
Gao, Yanfei
Xu, Wenping
Pan, Hongming
FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062

← 1 2 3 4 5 →